- U.S. Patent and Trademark Office awards Company
additional patent for PURE EP™ System
- Five patent applications filed by ViralClear
Pharmaceuticals, Inc., covering its orally administered
broad-spectrum anti-viral solution for the treatment of
COVID-19
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing a
proprietary biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals, today announced that the U.S. Patent and
Trademark Office (USPTO) has issued patent No. 10,645,017 titled
“Systems, Apparatus and Methods for Conveying Biomedical Signals
between a Patient and Monitoring and Treatment Devices,” which is
intended to broadly protect the Company’s flagship product – the
PURE EP(tm) System.
The claims address foundational systems and devices which help
with the recording, measuring, calculating and displaying of
electrocardiograms during cardiac ablation procedures for
conditioning cardiac (e.g., ECG and intercardiac) and other
physiologic signals, specifically to clearly define and record
low-amplitude, low-frequency information, which may be acquired
during ablation and other similar large-signal perturbations, such
as pacing and stimulation, without the presence of electrical
noise.
“This patent reinforces the continued protection of our PURE
EP(tm) System designed to enable electrophysiologists to achieve
clear visualization of cardiac signals with high fidelity and low
electrical noise during ablation procedures, which we believe may
lead to improved success rates for AF procedures,” commented
Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
“We continue to grow our intellectual property portfolio, expanding
our first mover advantage in the electrophysiology digital signal
processing and analysis space with our innovative
platform.”
BioSig also announced that its majority-owned subsidiary,
ViralClear Pharmaceuticals, Inc, has recently filed five new
provisional patent applications of its own over the last two months
with claims directed to methods of treating or preventing an
infectious disease caused by a coronavirus in a human or animal by
administering merimepodib, a broad-spectrum anti-viral. The patents
also address methods of inhibiting coronavirus replication in a
human or animal by administering merimepodib as a single agent or
in combination with other therapeutic agents, e.g., antiviral
agents, immune modulators, etc., such as remdesivir, as well as
novel oral and IV drug formulations for merimepodib
administration.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About Merimepodib (MMPD) Merimepodib, a
broad-spectrum anti-viral candidate, has demonstrated strong
activity against COVID-19 in cell cultures in laboratory
testing. Merimepodib was previously in development as a
treatment for chronic hepatitis C and psoriasis by Vertex
Pharmaceuticals Incorporated (Vertex), with 12 clinical trials
conducted (including 315 chronic hepatitis C patients, 24 psoriasis
patients, and 98 healthy volunteers) and an extensive preclinical
safety package completed.
A manuscript titled, “The IMPDH inhibitor merimepodib provided
in combination with the adenosine analogue remdesivir reduces
SARS-CoV-2 replication to undetectable levels in vitro”, was
submitted to an online peer-reviewed life sciences journal. This
manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler,
Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler
of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of
ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding
author. This article highlights pre-clinical data generated under
contract with Galveston National Laboratory at The University of
Texas Medical Branch.
About ViralClear BioSig’s subsidiary,
ViralClear Pharmaceuticals, Inc., is seeking to develop a novel
pharmaceutical to treat COVID-19. Merimepodib is intended to be
orally administered, and has demonstrated broad-spectrum in vitro
antiviral activity, including strong activity against COVID-19 in
cell cultures. Merimepodib has been previously studied in 12
clinical trials, including 5 in patients with hepatitis C (1 Phase
1b, 1 Phase 2, 2 Phase 2a, and 1 Phase 2b), 1 in patients with
psoriasis (Phase 2), and six in healthy volunteers (Phase I).
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024